## Company Update/Target price change



# **Godrej Consumer Products**

### Innovation to pay off

India | FMCG

#### Focus on building product categories to drive growth

Godrej Consumer Products (GCPL IN) is focused on elevating and its product portfolio through innovation democratization to drive penetration. The company is looking to introduce a new product in home insecticides (HI), which will focus on the efficacy, a potential game-changer. Additionally, it is entering into liquid space with the launch of liquid detergent, Godrej Fab, at a disruptive price of INR 99 per liter in select southern markets, and it also will explore the body wash category. The recent launch of affordable hair color packs at INR 15 has been well received, and it is aimed at increasing market penetration and upgrading consumers from traditional formats, such as hair color powder and henna.

#### Innovation in HI could be a game-changer

GCPL is in the process of launching a differentiated product in domestic HI, with a focus on boasting efficacy. This innovation has the potential to reshape the growth trajectory of the entire category. It has successfully implemented similar strategies in Indonesia and Bangladesh where the company has posted robust double-digit growth. With a patented and exclusive formulation, it will stand to gain a significant first-mover advantage, anticipating revival of growth in the HI segment, which reported a low single-digit growth during FY18-23.

#### Positive outlook for the international business

The company is poised for sustained double-digit constant currency (CC) growth in the international markets of Indonesia and the African Union (AU). In Indonesia, new product launch in the HI segment and go-to-market strategy are yielding positive results, ensuring growth in the medium to long term. Similarly, a revised go-to-market approach in the AU has bolstered performance in the western and southern regions.

#### Margin improvement on the cards

We expect overall margin to rise to 22.9% in FY26E from 18.3% in FY23. This improvement would be driven by cost synergy and scale benefits in recently acquired Raymond Consumer care business, a better mix in the domestic space due to resurgence in HI, enhanced margin in the overseas businesses, and a simplified East Africa operation by shifting to a royalty model.

#### Valuation: retain Accumulate with a higher TP of INR 1,230

We largely retain our estimates during FY24-25 and upgrade FY26 estimates by 3.7% to factor in a better margin profile. We reiterate Accumulate with a higher TP of INR 1,230 from INR 1,120 on 45x (unchanged) FY26E P/E as we roll forward. However, we have yet factor in the success of new launch in HI into our estimates, which could lead to improved revenue growth and profitability.

### Rating: Accumulate

Target Price: INR 1,230

**Upside: 17%** 

CMP: INR 1,050 (as on 20 December 2023)

Key data*	
Bloomberg / Reuters Code	GCPL IN/GOCP.BO
Current /Dil. Shares O/S (mn)	1,023/1,023
Mkt Cap (INR bn/USD mn)	1,074/12,915
Daily Vol. (3M NSE Avg.)	842,683
Face Value (INR)	1

#### 1 USD = INR 83.2

Pricing \*as on 20 December 2023; Source: Bloomberg

#### Price & Volume 1.200 6.0 1 000 4.0 800 2.0 600 Vol. in mn (RHS) -Godrej Consumer (LHS)

Source: Bloomberg

Shareholding (%)	Q3FY23	Q4FY23	Q1FY24	Q2FY24
Promoter	63.2	63.2	63.2	63.2
Institutional Investors	30.8	30.8	30.9	31.2
Other Investors	1.5	1.5	1.5	1.4
General Public	4.6	4.4	4.4	4.2
Source: BSE				

Price performance (%)	3M	6M	12M
Nifty	6.3	12.4	15.0
Godrej Consumer	6.1	(2.0)	17.4
Colgate	18.4	44.1	48.4
Dabur	(4.7)	(6.5)	(7.7)

Source: Bloomberg

YE	Revenue	YoY	EBITDA	EBITDA	Adj PAT	YoY	Fully DEPS	RoE	RoCE	P/E	EV/EBITDA
March	(INR mn)	(%)	(INR mn)	margin (%)	(INR mn)	(%)	(INR)	(%)	(%)	(x)	(x)
FY23	133,160	8.5	24,305	18.3	17,566	(2.0)	17.2	13.9	18.1	61.3	44.6
FY24E	144,750	8.7	29,292	20.2	19,956	13.6	19.5	14.4	18.1	54.0	36.5
FY25E	157,465	8.8	34,948	22.2	24,099	20.8	23.6	16.4	20.5	44.7	30.2
FY26E	175,210	11.3	40,092	22.9	27,897	15.8	27.3	17.2	20.7	38.6	26.0




### Consolidated Financials (YE March)

Income statement (INR mn)	FY23	FY24E	FY25E	FY26
Net Revenue	133,160	144,750	157,465	175,21
EBITDA	24,305	29,292	34,948	40,09
Less: Depreciation & Amortization	2,363	2,431	2,580	2,72
EBIT	21,942	26,861	32,368	37,36
Less: Interest Expense	1,757	3,100	2,600	2,60
Add: Other Income	1,684	1,358	1,603	1,65
Exceptional item	(541)	_	_	
PBT .	21,327	25,119	31,372	36,41
Less Taxes	4,303	5,173	7,282	8,52
Reported PAT	17,025	19,946	24,089	27,88
Minority Interest / Profit from JV and		(10)	(10)	/10
associates	-	(10)	(10)	(10
Reported PAT after Minority Interest	17,025	19,956	24,099	27,89
Adjusted PAT	17,566	19,956	24,099	27,89
Balance Sheet (INR mn)	FY23	FY24E	FY25E	FY26
Share capital	1,023	1,023	1,023	1,02
Reserves	136,920	139,162	153,257	169,76
Borrowings	10,340	38,590	28,340	28,34
Deferred Tax (Net)	(6,412)	(6,363)	(6,863)	(7,363
Total Liabilities	141,870	172,411	175,756	191,76
Gross Block	54,168	56,418	58,668	60,91
Less: Accumulated depreciation	13,015	15,447	18,027	20,75
Net Block	41,152	40,971	40,641	40,16
Capital work in progress	416	416	416	41
Goodwill	58,223	58,223	58,223	58,22
Investments	30,290	30,290	30,290	30,29
Cash	3,907	46,736	48,442	63,84
Net working capital	7,882	(4,224)	(2,255)	(1,167
Total Assets	141,870	172,411	175,756	191,76
Cash flow statement (INR mn)	FY23	FY24E	FY25E	FY26
Operating cash flow	22,298	34,493	24,711	29,53
Less: Capex	8,796	2,250	2,250	2,25
Free cash flow to firm	13,501	32,243	22,461	27,28
Investing cash flow	(28,932)	(2,250)	(2,250)	(2,250
Financing cash flow	(536)	10,585	(20,754)	(11,885
Net change in cash	(7,170)	42,828	1,707	15,40
Ratio Analysis	FY23	FY24E	FY25E	FY26
Income statement Ratios (%)				
Revenue growth	8.5	8.7	8.8	11.
EBITDA growth	1.5	20.5	19.3	14.
PAT growth	(2.0)	13.6	20.8	15.
EBITDA margin	18.3	20.2	22.2	22.
Net margin	13.2	13.8	15.3	15.
Return and liquidity ratios	13.2	15.0	15.5	1 ).
Net debt/Equity (x)	0.0	(0.1)	(0.1)	10.5
ROE (%)	13.9	14.4	(0.1) 16.4	(0.2 17.
ROE (%)	13.9	18.1	20.5	
ROCE (%) Per share data and Valuation ratios	10.1	10.1	20.5	20.
	17 7	10 5	22/	27
Diluted EPS (INR)	17.2	19.5	23.6	27.
EPS growth (%)	(2.0)	13.6	20.8	15.
DPS (INR)	-	8.3	9.8	11.
P/E (x)	61.3	54.0	44.7	38.
LV/LDITDA (v)	44.6	36.5	30.2	26.
, , ,		7.4	6.7	5.
EV/Sales (X)	8.1			
EV/EBITDA (x) EV/Sales (X) Price/Book(x)	8.4	7.7	7.0	6.
EV/Sales (X)				6. 2.


Note: pricing as on 20 December 2023; Source: Company, Elara Securities Estimate

#### Revenue growth & margin trend




Source: Company, Elara Securities Estimate

#### Adjusted profit growth trend



Source: Company, Elara Securities Estimate

#### **Return ratios**



Source: Company, Elara Securities Estimate



Exhibit 1: HI has been a laggard for the past five years; GCPL is taking steps to revive the segment

		<u> </u>
India business segments	FY18-23 revenue CAGR (%)	Comment
Household insecticide	Low single-digit	<ul> <li>GCPL is set to introduce a unique, highly effective product in the home insecticide segment, with the potential to significantly impact the category's growth trajectory.</li> <li>The patented formula, applied across products in HI, provides GCPL a significant first-mover advantage.</li> <li>Successfully implementing similar strategies in Indonesia and Bangladesh which have resulted in double-digit growth</li> <li>This launch is expected to rejuvenate GCPL's growth in the HI segment</li> </ul>
Personal wash	~10	<ul> <li>GCPL focuses on customer satisfaction by offering top-quality products at competitive prices</li> <li>It plans to enter the body wash category only when it identifies a product with the potential to impact the market, addressing current penetration challenges</li> </ul>
Hair colour	~6	<ul> <li>Affordable hair color packs at INR 15 are gaining popularity, targeting market expansion and encouraging consumers to switch from traditional options, such as hair color powder and <i>mehendi</i></li> <li>The recent launches aim to bolster penetration of crème and shampoo hair color, which have risen from 10-12% to sub-20% in the past 5-6 years</li> </ul>
Air freshener and others	Double digits	<ul> <li>Air freshener is thriving, showing double-digit growth. The newly launched AerO car fragrance is gaining momentum and has the potential to post significant growth. The high-margin Aer business can enhance domestic profitability</li> <li>GCPL is present in the liquid detergent space with brands such as Genteel, Ezee, and Fab. Genteel acts as both fabric conditioner and stain remover while Ezee caters to winterwear with added micro conditioners</li> <li>The disruptive launch of Godrej Fab at INR 99 per liter in select southern markets targets a mass consumer audience</li> </ul>

Source: Company, Elara Securities Research

Exhibit 2: GCPL category penetration low in India

Category penetration (%)	FY21
Liquid vaporisers	28
Liquid detergent	20
Hair colour crème	13
Bodywash	2

Source: Hindustan Unilever, Company, Elara Securities Research


Exhibit 3: Initiatives in place to deliver double-digit CC growth in the international markets

Region	FY18-23 revenue CAGR (%)	Comment
Indonesia	4	<ul> <li>Indonesia continues to deliver double-digit CC growth, aided by the change in go-to-market strategy and launch in HI</li> <li>GCPL expects strong performance to continue in the medium term for the next few quarters</li> <li>The company aims to revive margin into the mid-20s in the next couple of years from high teens margin</li> </ul>
GAUM (African Union the US and the Middle East)		<ul> <li>A revised go-to-market approach in the African Union has bolstered performance in the western and southern regions.</li> <li>It aims to optimize the East African dry hair fashion business by adopting a royalty-based model, bolstering profitability by INR 500mn at the PAT level by FY25E</li> </ul>

Source: Company, Elara Securities Research




Exhibit 4: We expect a revenue CAGR of 9.6% during FY23-26E



Source: Company, Elara Securities Estimate

Exhibit 5: EBITDA margin to expand ~450bp during FY23-26E



Source: Company, Elara Securities Estimate

Exhibit 6: GCPL is trading around its five-year average P/E of 45x



Source: Bloomberg, Company, Elara Securities Estimate

**Exhibit 7: Change in estimates** 

		Old			Revised		C	hange (%)	
(INR mn)	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E
Revenue	145,171	159,724	174,421	144,750	157,465	175,210	(0.3)	(1.4)	0.5
EBITDA	29,194	34,875	38,770	29,292	34,948	40,092	0.3	0.2	3.4
EBITDA (%)	20.1	21.8	22.2	20.2	22.2	22.9	12.6	36.0	65.4
PAT	19,879	24,046	26,900	19,956	24,099	27,897	0.4	0.2	3.7
EPS (INR)	19.4	23.5	26.3	19.5	23.6	27.3	0.4	0.2	3.7
TP (INR)			1,120			1,230			9.8

Source: Elara Securities Estimate



## **Coverage History**



AC=Analyst change

	Date	Rating	Target Price	Closing Price
21	19-May-2022	Accumulate	INR 900	INR 796
22	3-Aug-2022	Accumulate	INR 960	INR 862
23	7-Nov-2022	Accumulate	INR 915	INR 827
24	31-Jan-2023	Accumulate	INR 1,050	INR 913
25	28-Apr-2023	Accumulate	INR 963	INR 908
26	11-May-2023	Accumulate	INR 1,050	INR 983
27	2-Jun-2023	Reduce	INR 1,050	INR 1,061
28	7-Aug-2023	Accumulate	INR 1,120	INR 1,031
29	20-Dec-2023	Accumulate	INR 1,230	INR 1,050

# **Guide to Research Rating**

BUY	Absolute Return >+20%
ACCUMULATE	Absolute Return +5% to +20%
REDUCE	Absolute Return -5% to +5%
SELL	Absolute Return < -5%

### Elara Securities (India) Private Limited



#### Disclosures & Confidentiality for non U.S. Investors

The Note is based on our estimates and is being provided to you (herein referred to as the "Recipient") only for information purposes. The sole purpose of this Note is to provide preliminary information on the business activities of the company and the projected financial statements in order to assist the recipient in understanding / evaluating the Proposal. Nothing in this document should be construed as an advice to buy or sell or solicitation to buy or sell the securities of companies referred to in this document. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. Nevertheless, Elara Securities (India) Private Limited or any of its affiliates is committed to provide independent and transparent recommendation to its client and would be happy to provide any information in response to specific client queries. Elara Securities (India) Private Limited or any of its affiliates have not independently verified all the information given in this Note and expressly disclaim all liability for any errors and/or omissions, representations or warranties, expressed or implied as contained in this Note. The user assumes the entire risk of any use made of this information. Elara Securities (India) Private Limited or any of its affiliates, their directors and the employees may from time to time, effect or have effected an own account transaction in or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for or solicit investment banking or other business from any company referred to in this Note. Each of these entities functions as a separate, distinct and independent of each other. This Note is strictly confidential and is being furnished to you solely for your information. This Note should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This Note is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Elara Securities (India) Private Limited or any of its affiliates to any registration or licensing requirements within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law, and persons in whose possession this document comes, should inform themselves about and observe, any such restrictions. Upon request, the Recipient will promptly return all material received from the company and/or the Advisors without retaining any copies thereof. The Information given in this document is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This Information is subject to change without any prior notice. Elara Securities (India) Private Limited or any of its affiliates reserves the right to make modifications and alterations to this statement as may be required from time to time. However, Elara Securities (India) Private Limited is under no obligation to update or keep the information current. Neither Elara Securities (India) Private Limited nor any of its affiliates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. This Note should not be deemed an indication of the state of affairs of the company nor shall it constitute an indication that there has been no change in the business or state of affairs of the company since the date of publication of this Note. The disclosures of interest statements incorporated in this document are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. Elara Securities (India) Private Limited generally prohibits its analysts, persons reporting to analysts and their family members from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Any clarifications / queries on the proposal as well as any future communication regarding the proposal should be addressed to Elara Securities (India) Private Limited. It is important to note that any dispute with respect to this research report, would not have access to stock exchange investor redressal forum or arbitration mechanism.

Elara Securities (India) Private Limited was incorporated in July 2007 as a subsidiary of Elara Capital (India) Private Limited.

Elara Securities (India) Private Limited is a SEBI registered Stock Broker in the Capital Market and Futures & Options Segments of National Stock Exchange of India Limited [NSE], in the Capital Market Segment of BSE Limited [BSE] and a Depository Participant registered with Central Depository Services (India) Limited [CDSL].

Elara Securities (India) Private Limited's business, amongst other things, is to undertake all associated activities relating to its broking business.

The activities of Elara Securities (India) Private Limited were neither suspended nor has it defaulted with any stock exchange authority with whom it is registered in last five years. However, during the routine course of inspection and based on observations, the exchanges have issued advise letters or levied minor penalties on Elara Securities (India) Private Limited for minor operational deviations in certain cases. Elara Securities (India) Private Limited has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has the certificate of registration been cancelled by SEBI at any point of time.

Elara Securities (India) Private Limited offers research services primarily to institutional investors and their employees, directors, fund managers, advisors who are registered or proposed to be registered.

Details of Associates of Elara Securities (India) Private Limited are available on group company website www.elaracapital.com

Elara Securities (India) Private Limited is maintaining arms-length relationship with its associate entities.

Research Analyst or his/her relative(s) may have financial interest in the subject company. Elara Securities (India) Private Limited does not have any financial interest in the subject company, whereas its associate entities may have financial interest. Research Analyst or his/her relative does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Elara Securities (India) Private Limited does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Associate entities of Elara Securities (India) Private Limited may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Research Analyst or his/her relative or Elara Securities (India) Private Limited or its associate entities does not have any other material conflict of interest at the time of publication of the Research Report.

Research Analyst or his/her relative(s) has not served as an officer, director or employee of the subject company.

Research analyst or Elara Securities (India) Private Limited have not received any compensation from the subject company in the past twelve months. Associate entities of Elara Securities (India) Private Limited may have received compensation from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities have not managed or co-managed public offering of securities for the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associates have not received any compensation for investment banking or brokerage services from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company or third party in connection with the Research Report in the past twelve months.

#### Disclaimer & Standard warning

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.



### Elara Securities (India) Private Limited

#### Disclaimer for non U.S. Investors

The information contained in this note is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation.

#### Disclosures for U.S. Investors

The research analyst did not receive compensation from Godrej Consumer Products Limited.

Elara Capital Inc.'s affiliate did not manage an offering for Godrej Consumer Products Limited.

Elara Capital Inc.'s affiliate did not receive compensation from Godrej Consumer Products Limited in the last 12 months.

Elara Capital Inc.'s affiliate does not expect to receive compensation from Godrej Consumer Products Limited in the next 3 months.

#### Disclaimer for U.S. Investors

This material is based upon information that we consider to be reliable, but Elara Capital Inc. does not warrant its completeness, accuracy or adequacy and it should not be relied upon as such.

This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities, financial instruments or strategies mentioned herein may not be suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only correct as of the stated date of their issue. Prices, values or income from any securities or investments mentioned in this report may fall against the interests of the investor and the investor may get back less than the amount invested. Where an investment is described as being likely to yield income, please note that the amount of income that the investor will receive from such an investment may fluctuate. Where an investment or security is denominated in a different currency to the investor's currency of reference, changes in rates of exchange may have an adverse effect on the value, price or income of or from that investment to the investor. The information contained in this report does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation of particular securities, financial instruments or strategies to you. Before acting on any recommendation in this material, you should consider whether it is suitable for your particular circumstances and, if necessary, seek professional advice.

Certain statements in this report, including any financial projections, may constitute "forward-looking statements." These "forward-looking statements" are not guarantees of future performance and are based on numerous current assumptions that are subject to significant uncertainties and contingencies. Actual future performance could differ materially from these "forward-looking statements" and financial information.

### Elara Securities (India) Private Limited

Managing Director



India Elara Securities (India) Pvt. Ltd.

Harendra Kumar

Sales

One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India Tel : +91 22 6164 8500

Europe Elara Capital Plc. Edira Capital Mc. 6th Floor, The Grove, 248A Marylebone Road, London, NW1 6JZ, United Kingdom Tel: +44 20 7486 9733

USA Elara Securities Inc. 230 Park Avenue, Suite 2415, New York, NY 10169, USA Tel: +1 212 430 5870 Fax: +1 212 208 2501

harendra.kumar@elaracapital.com

Asia / Pacific Elara Capital (Asia) Pte.Ltd. One Marina Boulevard, Level 20, Singapore 018989 Tel: +65 6978 4047

+91 22 6164 8571

Tina D'souza  Quantitative, Alternatives, Sales Tradii Sunil Jain Nandish Patel Guar Biren Mehta Kalpesh Parekh India Anil Pawar India Anil Pawar India Nilesh Chheda India Nupur Barve India Nupur Barve Research D' Biron Pathiparampil Analyst Ankita Shah Biju Samuel Gagan Dixit Garima Kapoor Harshit Kapadia Analyst Lay Kale, CFA Analyst Karan Taurani Analyst Karan Taurani Analyst	a a a a a a a a a a a a a a a a a a a	ashok.agarwal@elaracapital.com hitesh.danak@elaracapital.com karan.rathod@elaracapital.com lekha.nahar@elaracapital.com prashin.lalvani@elaracapital.com shraddha.shrikhande@elaracapital.com sudhanshu.rajpal@elaracapital.com joshua.saldanha@elaracapital.com tiss anita.nazareth@elaracapital.com sunil.jain@elaracapital.com sunil.jain@elaracapital.com nandish.patel@elaracapital.com kalpesh.parekh@elaracapital.com manoj.murarka@elaracapital.com anil.pawar@elaracapital.com nilesh.chheda@elaracapital.com nupur.barve@elaracapital.com	+91 22 6164 8558 +91 22 6164 8543 +91 22 6164 8512 +91 22 6164 8544 +91 22 6164 8567 +91 22 6164 8568 +91 22 6164 8544 +91 22 6164 8541 +91 22 6164 8541 +91 22 6164 8555 +91 22 6164 8551 +91 22 6164 8555 +91 22 6164 8555 +91 22 6164 8555 +91 22 6164 8551 +91 22 6164 8555
Hitesh Danak India Karan Rathod India Lekha Nahar India Prashin Lalvani India Shraddha Shrikhande India Sudhanshu Rajpal India Joshua Saldanha Asia Anita Nazareth Corpr Tina D'souza Co	a a a a a a a a a a a a a a a a a a a	hitesh.danak@elaracapital.com karan.rathod@elaracapital.com lekha.nahar@elaracapital.com prashin.lalvani@elaracapital.com shraddha.shrikhande@elaracapital.com sudhanshu.rajpal@elaracapital.com joshua.saldanha@elaracapital.com anita.nazareth@elaracapital.com tina.dsouza@elaracapital.com sunil.jain@elaracapital.com nandish.patel@elaracapital.com biren.mehta@elaracapital.com kalpesh.parekh@ElaraCapital.com manoj.murarka@elaracapital.com anil.pawar@elaracapital.com nilesh.chheda@elaracapital.com	+91 22 6164 8543 +91 22 6164 8570 +91 22 6164 8512 +91 22 6164 8567 +91 22 6164 8568 +91 22 6164 8541 +91 22 6164 8541 +91 22 6164 8541 +91 22 6164 8555 +91 22 6164 8564 +91 22 6164 8564 +91 22 6164 8551 +91 22 6164 8551 +91 22 6164 8551 +91 22 6164 8555
Karan Rathod India Lekha Nahar India Prashin Lalvani India Shriaddha Shrikhande India Sudhanshu Rajpal India Joshua Saldanha Asia Anita Nazareth Corp Tina D'souza Corp Quantitative, Alternatives, Sales Tradii Sunil Jain Quar Nandish Patel Quar Biren Mehta Head Kalpesh Parekh India Anil Pawar India Nilesh Chheda India Nupur Barve India Nupur Barve India Nupur Barve India Presserch Dr Bino Pathiparampil Head of Amit Purohit Analyst Ankita Shah Analyst Biju Samuel Analyst Gagan Dixit Analyst Garima Kapoor Econom Harshit Kapadia Analyst Lay Karan Taurani Analyst Karan Taurani	porate Access, Conference & Even porate Access ing & Dealing nitiative & Alternates nitiative & Alternates d - Sales Trading a a a a a a a a a a a a a a a a a a a	karan.rathod@elaracapital.com lekha.nahar@elaracapital.com prashin.lalvani@elaracapital.com shraddha.shrikhande@elaracapital.com sudhanshu.rajpal@elaracapital.com joshua.saldanha@elaracapital.com anita.nazareth@elaracapital.com tina.dsouza@elaracapital.com sunil.jain@elaracapital.com nandish.patel@elaracapital.com biren.mehta@elaracapital.com kalpesh.parekh@ElaraCapital.com manoj.murarka@elaracapital.com anil.pawar@elaracapital.com nilesh.chheda@elaracapital.com	+91 22 6164 8570 +91 22 6164 8512 +91 22 6164 8567 +91 22 6164 8508 +91 22 6164 8541 +91 22 6164 8541 +91 22 6164 8552 +91 22 6164 8551 +91 22 6164 8564 +91 22 6164 8564 +91 22 6164 8555 +91 22 6164 8555
Lekha Nahar India Prashin Lalvani India Shraddha Shrikhande India Sudhanshu Rajpal India Joshua Saldanha Asia Anita Nazareth Corpt Tina D'souza Corpt Quantitative, Alternatives, Sales Tradir Sunil Jain Quar Nandish Patel Quar Biren Mehta Head Kalpesh Parekh India Manoj Murarka India Anil Pawar India Nilesh Chheda India Nupur Barve India Nupur Barve India Namita Shah Analyst Ankita Shah Analyst Gagan Dixit Analyst Garima Kapoor Econom Harshit Kapadia Analyst Karan Taurani Analyst Karan Taurani	orate Access, Conference & Even corate Access, Conference & Even corate Access ing & Dealing ntitative & Alternates nitiative & Alternates d - Sales Trading a a a a a a f Research Healthcare, Pharmace Building Materials, Dai	lekha.nahar@elaracapital.com prashin.lalvani@elaracapital.com shraddha.shrikhande@elaracapital.com sudhanshu.rajpal@elaracapital.com joshua.saldanha@elaracapital.com inta.nazareth@elaracapital.com tina.dsouza@elaracapital.com sunil.jain@elaracapital.com nandish.patel@elaracapital.com biren.mehta@elaracapital.com kalpesh.parekh@ElaraCapital.com manoj.murarka@elaracapital.com anil.pawar@elaracapital.com nilesh.chheda@elaracapital.com	+91 22 6164 8512 +91 22 6164 8564 +91 22 6164 8567 +91 22 6164 8508 +91 22 6164 8541 +91 22 6164 8520 +91 22 6164 8595 +91 22 6164 8531 +91 22 6164 8564 +91 22 6164 8555 +91 22 6164 8555 +91 22 6164 8555 +91 22 6164 8555
Prashin Lalvani India Shraddha Shrikhande India Sudhanshu Rajpal India Joshua Saldanha Asia Anita Nazareth Corpo Tina D'souza Corpo Quantitative, Alternatives, Sales Tradir Sunil Jain Quar Nandish Patel Quar Biren Mehta Head Manoj Murarka India Manoj Murarka India Nilesh Chheda India Nilesh Chheda India Nilesh Chheda India Nilesh Chheda India Rupur Barve India Pawar India Nilesh Chheda India Supur Barve India Pawar India Nilesh Chheda India Supur Barve India Nilesh Chheda India Nilesh Chada India Nilesh Chada India Nilesh Chada India Nalyst Analyst Analyst Gagan Dixit Analyst Garima Kapoor Econom Harshit Kapadia Analyst Karan Taurani Analyst Karan Taurani	orate Access, Conference & Even porate Access ing & Dealing nitiative & Alternates ntitative & Alternates d - Sales Trading a a a a f Research Healthcare, Pharmace Building Materials, Dai	prashin.lalvani@elaracapital.com shraddha.shrikhande@elaracapital.com sudhanshu.rajpal@elaracapital.com joshua.saldanha@elaracapital.com anita.nazareth@elaracapital.com tina.dsouza@elaracapital.com sunil.jain@elaracapital.com nandish.patel@elaracapital.com biren.mehta@elaracapital.com kalpesh.parekh@ElaraCapital.com manoj.murarka@elaracapital.com anil.pawar@elaracapital.com nilesh.chheda@elaracapital.com	+91 22 6164 8544 +91 22 6164 8567 +91 22 6164 8508 +91 22 6164 8541 +91 22 6164 8520 +91 22 6164 8595 +91 22 6164 8531 +91 22 6164 8564 +91 22 6164 8555 +91 22 6164 8555 +91 22 6164 8555
Shraddha Shrikhande India Sudhanshu Rajpal India Joshua Saldanha Asia Anita Nazareth Corpt Tina D'souza Corpt Quantitative, Alternatives, Sales Tradii Suniil Jain Quar Nandish Patel Quar Biren Mehta Head Kalpesh Parekh India Manoj Murarka India Anil Pawar India Nilesh Chheda India Nupur Barve India Nupur Barve India Nupur Barve India Pawista Shah Analyst Ankita Shah Analyst Ankita Shah Analyst Gagan Dixit Analyst Garima Kapoor Econom Harshit Kapadia Analyst Karan Taurani Analyst Karan Taurani	porate Access, Conference & Even porate Access ing & Dealing nitiative & Alternates ntitative & Alternates d - Sales Trading a a a a a a a a a a a a a a a a a a a	shraddha.shrikhande@elaracapital.com sudhanshu.rajpal@elaracapital.com joshua.saldanha@elaracapital.com anita.nazareth@elaracapital.com tina.dsouza@elaracapital.com sunil.jain@elaracapital.com nandish.patel@elaracapital.com biren.mehta@elaracapital.com kalpesh.parekh@ElaraCapital.com manoj.murarka@elaracapital.com anil.pawar@elaracapital.com nilesh.chheda@elaracapital.com	+91 22 6164 8567 +91 22 6164 8508 +91 22 6164 8541 +91 22 6164 8520 +91 22 6164 8595 +91 22 6164 8564 +91 22 6164 8560 +91 22 6164 8555 +91 22 6164 8555
Sudhanshu Rajpal India Joshua Saldanha Asia Anita Nazareth Corpt Tina D'Souza Corpt Quantitative, Alternatives, Sales Tradit Sunil Jain Quar Randish Patel Quar Biren Mehta Head Kalpesh Parekh India Manoj Murarka India Anil Pawar India Nilesh Chheda India Nupur Barve India Nupur Barve India Research  Pr Bino Pathiparampil Head of Amit Purohit Analyst Ankita Shah Analyst Biju Samuel Analyst Gagan Dixit Analyst Garima Kapoor Econom Harshit Kapadia Analyst Lay Kale, CFA Analyst Karan Taurani Analyst Karpan Suran Sales Taurani	porate Access, Conference & Even porate Access ing & Dealing Initiative & Alternates Initiative & I	sudhanshu.rajpal@elaracapital.com joshua.saldanha@elaracapital.com ts anita.nazareth@elaracapital.com tina.dsouza@elaracapital.com  sunil.jain@elaracapital.com nandish.patel@elaracapital.com biren.mehta@elaracapital.com kalpesh.parekh@ElaraCapital.com manoj.murarka@elaracapital.com anil.pawar@elaracapital.com nilesh.chheda@elaracapital.com	+91 22 6164 8508 +91 22 6164 8541 +91 22 6164 8520 +91 22 6164 8595 +91 22 6164 8531 +91 22 6164 8564 +91 22 6164 8500 +91 22 6164 8555 +91 22 6164 8555
Joshua Saldanha Asia Anita Nazareth Corpi Tina D'souza Corpo Quantitative, Alternatives, Sales Tradir Sunil Jain Quar Nandish Patel Quar Biren Mehta Head Kalpesh Parekh India Manoj Murarka India Anil Pawar India Nilesh Chheda India Nupur Barve India Nupur Barve India Research Dr Bino Pathiparampil Head of Amit Purohit Analyst Ankita Shah Analyst Gagan Dixit Analyst Gagan Dixit Analyst Garima Kapoor Econom Harshit Kapadia Analyst Karan Taurani Analyst Karan Taurani	orate Access, Conference & Even porate Access ing & Dealing ntitative & Alternates nitiative & Alternates d - Sales Trading a - Alternates d	joshua.saldanha@elaracapital.com anita.nazareth@elaracapital.com tina.dsouza@elaracapital.com sunil.jain@elaracapital.com nandish.patel@elaracapital.com biren.mehta@elaracapital.com kalpesh.parekh@ElaraCapital.com manoj.murarka@elaracapital.com anil.pawar@elaracapital.com nilesh.chheda@elaracapital.com	+91 22 6164 8541 +91 22 6164 8520 +91 22 6164 8595 +91 22 6164 8531 +91 22 6164 8564 +91 22 6164 8555 +91 22 6164 8555 +91 22 6164 8555 +91 22 6164 8555
Anita Nazareth Corportina D'souza Corportina D'souza Corportina D'souza Corportina D'souza Corportina D'souza Corportina D'souza Carla di Anita Calesta Calest	porate Access, Conference & Even porate Access ing & Dealing nitiative & Alternates nitiative & Alternates d - Sales Trading a a a a a f Research Healthcare, Pharmace Building Materials, Dai	anita.nazareth@elaracapital.com tina.dsouza@elaracapital.com sunil.jain@elaracapital.com nandish.patel@elaracapital.com biren.mehta@elaracapital.com kalpesh.parekh@ElaraCapital.com manoj.murarka@elaracapital.com anil.pawar@elaracapital.com nilesh.chheda@elaracapital.com	+91 22 6164 8520 +91 22 6164 8595 +91 22 6164 8531 +91 22 6164 8564 +91 22 6164 8555 +91 22 6164 8555 +91 22 6164 8551 +91 22 6164 8552
Tina D'souza  Corpo Quantitative, Alternatives, Sales Tradii Sunil Jain Quar Nandish Patel Guer Biren Mehta Head Kalpesh Parekh India Anil Pawar India Nilesh Chheda Nupur Barve India Nupur Barve India Research Dr Birno Pathiparampil Head of Amit Purohit Analyst Ankita Shah Biju Samuel Gagan Dixit Garima Kapoor Harshit Kapadia Analyst Lay Kale, CFA Analyst Karan Taurani Auduratives, Sales Tradii Quar Quar Research Dr Birno Pathiparampil Analyst Garima Kapoor Leconom Harshit Kapadia Analyst	porate Access Ing & Dealing Intitative & Alternates Intitative & Intitati	tina.dsouza@elaracapital.com  sunil.jain@elaracapital.com  nandish.patel@elaracapital.com  biren.mehta@elaracapital.com  kalpesh.parekh@ElaraCapital.com  manoj.murarka@elaracapital.com  anil.pawar@elaracapital.com  nilesh.chheda@elaracapital.com	+91 22 6164 8595 +91 22 6164 8531 +91 22 6164 8564 +91 22 6164 8500 +91 22 6164 8555 +91 22 6164 8551 +91 22 6164 8552
Quantitative, Alternatives, Sales Tradir       Sunil Jain     Quar       Nandish Patel     Quar       Biren Mehta     Head       Kalpesh Parekh     India       Manoj Murarka     India       Anil Pawar     India       Nilesh Chheda     India       Nupur Barve     India       Research       Dr Bino Pathiparampil     Head of       Amit Purohit     Analyst       Ankita Shah     Analyst       Gagan Dixit     Analyst       Garima Kapoor     Econom       Harshit Kapadia     Analyst       Jay Kale, CFA     Analyst       Karan Taurani     Analyst	ing & Dealing nitiative & Alternates ntitative & Alternates d - Sales Trading a a a a a f Research Healthcare, Pharmace Building Materials, Dai	sunil.jain@elaracapital.com nandish.patel@elaracapital.com biren.mehta@elaracapital.com kalpesh.parekh@ElaraCapital.com manoj.murarka@elaracapital.com anil.pawar@elaracapital.com nilesh.chheda@elaracapital.com	+91 22 6164 8531 +91 22 6164 8564 +91 22 6164 8500 +91 22 6164 8555 +91 22 6164 8551 +91 22 6164 8552
Sunil Jain Quar Nandish Patel Quar Biren Mehta Head Kalpesh Parekh India Manoj Murarka India Nilesh Chheda India Nupur Barve India Nupur Barve India Pesearch  Tr Bino Pathiparampil Head of Amit Purohit Analyst Ankita Shah Analyst Gagan Dixit Garima Kapoor Econom Harshit Kapadia Analyst Karan Taurani Analyst Analyst Karan Taurani Analyst Analyst Karan Taurani	ntitative & Alternates ntitative & Alternates d - Sales Trading a a a a a a f Research Healthcare, Pharmace Building Materials, Dai	nandish.patel@elaracapital.com biren.mehta@elaracapital.com kalpesh.parekh@ElaraCapital.com manoj.murarka@elaracapital.com anil.pawar@elaracapital.com nilesh.chheda@elaracapital.com	+91 22 6164 8564 +91 22 6164 8500 +91 22 6164 8555 +91 22 6164 8551 +91 22 6164 8552
Nandish Patel Ouar Biren Mehta Head Kalpesh Parekh India Anil Pawar India Anil Pawar India Nupur Barve	ntitative & Alternates d - Sales Trading a a a a a a f Research Healthcare, Pharmace Building Materials, Dai	nandish.patel@elaracapital.com biren.mehta@elaracapital.com kalpesh.parekh@ElaraCapital.com manoj.murarka@elaracapital.com anil.pawar@elaracapital.com nilesh.chheda@elaracapital.com	+91 22 6164 8564 +91 22 6164 8500 +91 22 6164 8555 +91 22 6164 8551 +91 22 6164 8552
Nandish Patel Ouar Biren Mehta Head Kalpesh Parekh India Anil Pawar India Nilesh Chheda India Nupur Barve India Nupur Barve India Pesarch Tesarch Analyst Ankita Shah Analyst Ankita Shah Analyst Gagan Dixit Analyst Garima Kapoor Econom Harshit Kapadia Analyst Karan Taurani Analyst Karan Taurani Analyst Karan Taurani Analyst Karlong Analyst Garima Kapoor Analyst Garima Kapoor Analyst Karan Taurani Analyst Karan Taurani Analyst Karan Taurani Analyst Karlong Analyst Karan Taurani Analyst Analyst Karan Taurani	ntitative & Alternates d - Sales Trading a a a a a a f Research Healthcare, Pharmace Building Materials, Dai	nandish.patel@elaracapital.com biren.mehta@elaracapital.com kalpesh.parekh@ElaraCapital.com manoj.murarka@elaracapital.com anil.pawar@elaracapital.com nilesh.chheda@elaracapital.com	+91 22 6164 8564 +91 22 6164 8500 +91 22 6164 8555 +91 22 6164 8551 +91 22 6164 8552
Biren Mehta Head Kalpesh Parekh India Manoj Murarka India Anil Pawar India Nilesh Chheda India Nilesh Chhe	d - Sales Trading a a a a a a a f Research Healthcare, Pharmace Building Materials, Dai	biren.mehta@elaracapital.com kalpesh.parekh@ElaraCapital.com manoj.murarka@elaracapital.com anil.pawar@elaracapital.com nilesh.chheda@elaracapital.com	+91 22 6164 8500 +91 22 6164 8555 +91 22 6164 8551 +91 22 6164 8552
Kalpesh Parekh India Manoj Murarka India Anil Pawar India Nilesh Chheda India Nupur Barve India Nupur	f Research Healthcare, Pharmace Building Materials, Dai	kalpesh.parekh@ElaraCapital.com manoj.murarka@elaracapital.com anil.pawar@elaracapital.com nilesh.chheda@elaracapital.com	+91 22 6164 8555 +91 22 6164 8551 +91 22 6164 8552
Manoj Murarka India Anil Pawar India Nilesh Chheda India Nupur Barve India  Research  Dr Bino Pathiparampil Head of Amit Purohit Analyst Ankita Shah Analyst Gagan Dixit Analyst Garima Kapoor Econom Harshit Kapadia Analyst Jay Kale, CFA Analyst Karan Taurani Analyst	a a a a f Research Healthcare, Pharmace Building Materials, Dai	manoj.murarka@elaracapital.com anil.pawar@elaracapital.com nilesh.chheda@elaracapital.com	+91 22 6164 8551 +91 22 6164 8552
Anil Pawar India Nilesh Chheda India Nupur Barve India  Research  Dr Bino Pathiparampil Head of Amit Purohit Analyst Ankita Shah Analyst Gagan Dixit Analyst Garima Kapoor Econom Harshit Kapadia Analyst Jay Kale, CFA Analyst Karan Taurani Analyst	a a a f Research Healthcare, Pharmace Building Materials, Dai	anil.pawar@elaracapital.com nilesh.chheda@elaracapital.com	+91 22 6164 8552
Nilesh Chheda Nupur Barve  Research  Dr Bino Pathiparampil Head of Amit Purohit Analyst Biju Samuel Analyst Gagan Dixit Analyst Garima Kapoor Econom Harshit Kapadia Analyst Jay Kale, CFA Analyst Karan Taurani Analyst	a a f Research Healthcare, Pharmace Building Materials, Dai	nilesh.chheda@elaracapital.com	
Nupur Barve India  Research  Dr Bino Pathiparampil Head of Amit Purchit Analyst Ankita Shah Analyst Gagan Dixit Analyst Garima Kapoor Econom Harshit Kapadia Analyst Jay Kale, CFA Analyst Karan Taurani Analyst	a f Research Healthcare, Pharmace Building Materials, Dai		
Research  Dr Bino Pathiparampil Head of Amit Purohit Analyst Ankita Shah Analyst Gagan Dixit Analyst Garima Kapoor Econom Harshit Kapadia Analyst Jay Kale, CFA Analyst Karan Taurani Analyst	f Research Healthcare, Pharmace Building Materials, Dai	nupur.barve@elaracapital.com	+91 22 6164 8554
Dr Bino Pathiparampil Head of Amit Purohit Analyst Ankita Shah Analyst Biju Samuel Analyst Gagan Dixit Analyst Garima Kapoor Econom Harshit Kapadia Analyst Jay Kale, CFA Analyst Karan Taurani Analyst Analyst	Building Materials, Dai		+91 22 6164 8532
Dr Bino Pathiparampil Head of Amit Purohit Analyst Ankita Shah Analyst Biju Samuel Analyst Gagan Dixit Analyst Garima Kapoor Econom Harshit Kapadia Analyst Jay Kale, CFA Analyst Karan Taurani Analyst Analyst	Building Materials, Dai		
Amit Purohit Analyst Ankita Shah Analyst Biju Samuel Analyst Gagan Dixit Analyst Garima Kapoor Econom Harshit Kapadia Analyst Jay Kale, CFA Analyst Karan Taurani Analyst	Building Materials, Dai	uticals Strategy hipopathiparamoil@plaracaeital.com	+01 22 6164 0600
Ankita Shah Analyst Biju Samuel Analyst Gagan Dixit Analyst Garima Kapoor Econom Harshit Kapadia Analyst Jay Kale, CFA Analyst Karan Taurani Analyst			+91 22 6164 8689
Biju Samuel Analyst Gagan Dixit Analyst Garima Kapoor Econom Harshit Kapadia Analyst Jay Kale, CFA Analyst Karan Taurani Analyst			+91 22 6164 8594
Gagan Dixit Analyst Garima Kapoor Econom Harshit Kapadia Analyst Jay Kale, CFA Analyst Karan Taurani Analyst		Logistics, Industrials ankita.shah@elaracapital.com	+91 22 6164 8516
Garima Kapoor Econom Harshit Kapadia Analyst Jay Kale, CFA Analyst Karan Taurani Analyst			+91 22 6164 8505
Harshit Kapadia Analyst Jay Kale, CFA Analyst Karan Taurani Analyst			+91 22 6164 8504
Jay Kale, CFA Analyst Karan Taurani Analyst	nist	garima.kapoor@elaracapital.com	+91 22 6164 8527
Karan Taurani Analyst	Capital Goods, Consur	ner Electronics harshit.kapadia@elaracapital.com	+91 22 6164 8542
Karan Taurani Analyst			+91 22 6164 8507
		t, Alcobev, QSR, Internet karan.taurani@elaracapital.com	+91 22 6164 8513
Prakhar Agarwal Analyst		prakhar.agarwal@elaracapital.com	+91 22 6164 8502
Prashant Biyani Analyst			+91 22 6164 8581
Prerna Jhunjhunwala Analyst		prerna.jhunjhunwala@elaracapital.com	+91 22 6164 8519
Ravi Sodah Analyst			+91 22 6164 8517
Ruchi Mukhija Analyst		ruchi.mukhija@elaracapital.com	+91 22 6164 8583
Rupesh Sankhe Analyst		Capital Goods, Real Estate rupesh.sankhe@elaracapital.com	+91 22 6164 8518
Shweta Daptardar Analyst		Non Lending Financials shweta.daptardar@elaracapital.com	+91 22 6164 8559
Saurabh Mitra Sr. Assoc			+91 22 6164 8546
Aditya Jaiswal Associat	te Strategy	aditya.jaiswal@elaracapital.com	+91 22 4204 8683
Amogh Deshpande Associate	te Aviation, Chemicals, C	il & Gas amogh.deshpande@elaracapital.com	+91 22 4204 8664
Ash Shah Associate	te Infrastructure, Ports &	Logistics ash.shah@elaracapital.com	+91 22 6164 8500
Bhavi Shah Associate	te Cement, Metals & Min	ng bhavi.shah@elaracapital.com	+91 22 6164 8521
Gaurang Sakare Associate			+91 22 4204 8618
Heet Van Associate			+91 22 6164 8545
Himanshu Dhyawala Associate		Non Lending Financials himanshu.dhyawala@elaracapital.com	+91 22 4204 8661
		kartik.solanki@elaracapital.com	+91 22 4204 8604
Ketul Dalal Associate			+91 22 4204 8693
Keval Shah Associate		keval.shah@elaracapital.com	+91 22 4204 8669
Mudit Kabra Associate			+91 22 4204 8611
Nemish Sundar Associate			+91 22 4204 8683
Nishant Chowhan, CFA Associate			+91 22 4204 8667
Palak Shah Associate	te Banking & Financials	palak.shah@elaracapital.com	+91 22 6164 8500
Ragini Pande Associate	te Utilities, Renewables	ragini.pande@elaracapital.com	+91 22 6164 8500
Rohit Harlikar Associate			+91 22 6164 8562
Rounak Ray Associate		t, Alcobev, QSR, Internet rounak.ray@elaracapital.com	+91 22 4204 8684
Seema Nayak Associate		seema.nayak@elaracapital.com	+91 22 4204 8687
Shweta Roy Associate		shweta.roy@elaracapital.com	+91 22 6164 8500
Subhankar Sanyal Associate		subhankar.sanyal@elaracapital.com	+91 22 4204 8688
Tanvi Tambat Associate		tanvi.tambat@elaracapital.com	+91 22 6164 8537
Ujwal Wadighare Associate		ujwal.wadighare@elaracapital.com	+91 22 6164 8500
Vaibhav Chechani Associate		vaibhav.chechani@elaracapital.com	+91 22 4204 8682
Vidhi Puj Associat			+91 22 4204 8692
Vinayak Patil Databas	se	vinayak.patil@elaracapital.com	+91 22 6164 8510
Priyanka Sheth Editor		priyanka.sheth@elaracapital.com	+91 22 6164 8568
Prakriti Singh Editor		prakriti.singh@elaracapital.com	+91 22 6164 8500
Gurunath Parab Producti			
Jinesh Bhansali Producti	tion		
JII CSI I DI IGII ISGIII TOUUCU		gurunath.parab@elaracapital.com jinesh.bhansali@elaracapital.com	+91 22 6164 8515 +91 22 6164 8537

Access our reports on Bloomberg: Type RESP ESEC <GO>

Also available on Thomson & Reuters

Elara Securities (India) Private Limited

Registered Office Address: One International Center, Tower 3, 21st Floor, Senapati Bapat Marg,
Elphinstone Road (West) Mumbai – 400 013, India Tel: +91 22 6164 8500

CIN: U74992MH2007PTC172297 | SEBI Research Analyst Registration No.: INH000000933

Member of BSE Limited and National Stock Exchange of India Limited | SEBI REGN. NO.: INZ 000 238236 Member of Central Depository Services (India) Limited | SEBI REGN. NO.: IN-DP-370-2018 Investor Grievance Email ID: <u>investor.grievances@elaracapital.com</u> - Tel. +91 22 6164 8509 Compliance Officer: Mr. Anand Rao - Email ID: <u>anand.rao@elaracapial.com</u> - Tel. +91 22 6164 8509